.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,807,538

« Back to Dashboard

Details for Patent: 5,807,538

Title: Technetium-99m labeled peptides for imaging inflammation
Abstract:This invention relates to radiolabeled peptides and methods for producing such peptides. Specifically, the invention relates to technetium-99m (Tc-99m) labeled leukocyte-binding peptides, methods and kits for making such peptides, and methods for using such peptides to image sites of infection and inflammation in a mammalian body.
Inventor(s): Dean; Richard T. (Bedford, NH), Lees; Robert S. (Brookline, MA), Buttram; Scott (Derry, NH)
Assignee: Diatide, Inc. (Londonderry, NH)
Filing Date:Jun 07, 1995
Application Number:08/484,774
Claims:1. A complex formed by reacting a reagent comprising a leukocyte-binding chemotactic peptide covalently linked to a radiolabel-binding moiety selected from the group consisting of:

wherein Cp is a protected cysteine and (aa) is any primary .alpha.- or .beta.-amino acid;

a radiolabel-binding moiety comprising a single thiol-containing moiety having a formula

wherein

A is H, HOOC, H.sub.2 NOC, or NHOC;

B is H, SH, or NHR", where R" is H, lower alkyl, or --C.dbd.O;

X is SH or NHR", where R" is H, lower alkyl or --C.dbd.O;

R and R' are independently H or lower alkyl;

n is 0, 1, or 2;

and where B is NHR", X is SH and n is 1 or 2;

where X is NHR", B is SH and n is 1 or 2;

where B is H, X is SH and n is 0 or 1;

and wherein the thiol moiety is in the reduced form;

and a radiolabel-binding moiety of formula ##STR3## wherein each R is independently H, lower alkyl having one to six carbon atoms, phenyl, or phenyl substituted with lower alkyl or lower alkoxy, and wherein each n is independently one or 2,

with technetium-99m in the presence of a reducing agent, wherein the complex is capable of accumulating at a site of inflammation in a mammalian body.

2. The complex of claim 1, wherein the reducing agent is selected from the group consisting of a dithionite ion, a stannous ion, a solid-phase reducing agent, and a ferrous ion.

3. The complex of claim 1, formed by ligand exchange of a prereduced technetium-99m complex.

4. A method for preparing an imaging agent for detecting infection or inflammation in a mammalian body comprising the steps of

a) providing a reagent comprising a leukocyte-binding chemotactic peptide covalently linked to a radiolabel-binding moiety selected from the group consisting of

wherein Cp is a protected cysteine and (aa) is any primary .alpha.- or .beta.-amino acid;

a radiolabel-binding moiety comprising a single thiol-containing moiety having a formula

wherein

A is H, HOOC, H.sub.2 NOC, or NHOC;

B is H, SH, or NHR", where R" is H, lower alkyl, or --C.dbd.O;

X is SH or NHR", where R" is H, lower alkyl or --C.dbd.O;

R and R' are independently H or lower alkyl;

n is 0, 1, or 2;

and where B is NHR", X is SH and n is 1 or 2;

where X is NHR", B is SH and n is 1 or 2;

where B is H, X is SH and n is 0 or 1;

and wherein the thiol moiety is in the reduced form;

and a radiolabel-binding moiety of formula ##STR4## wherein each R is independently H, lower alkyl having one to six carbon atoms, phenyl, or phenyl substituted with lower alkyl or lower alkoxy, and wherein each n is independently one or 2, and

b) reacting the reagent with technetium-99m in the presence of a reducing agent.

5. The method of claim 4, wherein the reducing agent is selected from the group consisting of a dithionite ion, a stannous ion, a ferrous ion, and a solid-phase reducing agent.

6. A method for preparing an imaging agent for detecting infection or inflammation in a mammalian body comprising the steps of

a) providing a reagent comprising a leukocyte-binding chemotactic peptide covalently linked to a radiolabel-binding moiety selected from the group consisting of

wherein Cp is a protected cysteine and (aa) is any primary .alpha.- or .beta.-amino acid;

a radiolabel-binding moiety comprising a single thiol-containing moiety having a formula

wherein

A is H, HOOC, H.sub.2 NOC, or NHOC;

B is H, SH, or NHR", where R" is H, lower alkyl, or --C.dbd.O;

X is SH or NHR", where R" is H, lower alkyl or --C.dbd.O;

R and R' are independently H or lower alkyl;

n is 0, 1, or 2;

and where B is NHR", X is SH and n is 1 or 2;

where X is NHR", B is SH and n is 1 or 2;

where B is H, X is SH and n is 0 or 1;

and wherein the thiol moiety is in the reduced form;

and a radiolabel-binding moiety of formula ##STR5## wherein each R is independently H, lower alkyl having one to six carbon atoms, phenyl, or phenyl substituted with lower alkyl or lower alkoxy, and wherein each n is independently one or 2, and

b) labeling the reagent with technetium-99m by ligand exchange of a prereduced technetium-99m complex.

7. A complex formed by reacting technetium-99m with a reagent comprising a leukocyte-binding chemotactic peptide covalently linked to a radiolabel-binding moiety, wherein the technetium-99m complexed radiolabel-binding moiety has a net charge of -1, and wherein the complex is capable of accumulating at a site of inflammation in a mammalian body.

8. The complex of claim 7, formed by reacting the reagent with technetium-99m in the presence of a reducing agent.

9. The complex of claim 8, wherein the reducing agent is selected from the group consisting of a dithionite ion, a stannous ion, a solid-phase reducing agent, and a ferrous ion.

10. The complex of claim 7 formed by reacting the reagent with technetium-99m by ligand exchange of a prereduced technetium-99m complex.

11. A method for preparing an imaging agent for detecting infection or inflammation in a mammalian body comprising the steps of

a) providing a reagent comprising a leukocyte-binding chemotactic peptide covalently linked to a radiolabel-binding moiety capable of forming a complex with technetium-99m having a net charge of -1; and

b) labeling the reagent with technetium-99m by ligand exchange of a prereduced technetium-99m complex.

12. A complex formed by reacting technetium-99m with a reagent comprising a chemotactic peptide which binds to leukocytes covalently linked to a radiolabel-binding moiety, wherein the technetium-99m and the radiolabel-binding moiety form a neutral complex, and wherein the complex is capable of accumulating at a site of inflammation in a mammalian body.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc